Product Overview
[Drug Name]
Generic Name: Pantoprazole Sodium Enteric-Coated Capsules
Trade Name: DiWeiJian Pantoprazole Sodium Enteric-Coated Capsules 40mg x 14 Capsules
Pinyin Full Code: DiWeiJian ZuoTuoLaZuoNaChangRongJiaoNang 40mg x 14Li
[Main Ingredients]
The active ingredient of this product is pantoprazole sodium. Chemical Name: 5-Difluoromethoxy-2-[[(3,4-dimethoxy-2-pyridyl)methyl]-sulfinyl]-1H-benzimidazole sodium monohydrate. Molecular Formula: C₁₆H₁₄F₂N₃NaO₄S·H₂O. Molecular Weight: 423.38
[Properties]
This product is an enteric-coated tablet that appears white or off-white after removal of the coating.
[Indications/Main Functions]
Indicated for active peptic ulcers (gastric and duodenal ulcers), reflux esophagitis, and Zollinger-Ellison syndrome.
[Specifications]
40mg x 14 Capsules
[Dosage and Administration]
Take 40 mg (1 tablet) orally daily before breakfast. The treatment course for duodenal ulcers is usually 2-4 weeks, while the treatment course for gastric ulcers and reflux esophagitis is usually 4-8 weeks.
[Adverse Reactions]
Clinical symptoms include dizziness, insomnia, drowsiness, nausea, diarrhea and constipation, rash, and muscle pain.
[Contraindications]
This product is contraindicated in patients allergic to it, breastfeeding women, and women in the first trimester of pregnancy.
[Drug Interactions]
Oxytoprazole has minimal interactions with other drugs. Compared to omeprazole, it has a lesser effect on the cytochrome P450 system and does not affect the duration of diazepam action. It has no significant interactions with oral contraceptives, digoxin, warfarin, phenytoin, or theophylline.
[Precautions]
1. High doses may cause arrhythmia, elevated transaminases, changes in renal function, and decreased granulocyte counts. 2. This product is an enteric-coated formulation and should not be chewed. 3. When gastric ulcers are suspected, cancer should be ruled out first, as this product may alleviate symptoms and delay diagnosis. 4. Efficacy and safety data for this product in children have not been established. 5. Use with caution in patients with hepatic and renal impairment.
[Pediatric Use]
Efficacy and safety data for this product in children have not been established. It is contraindicated in infants and young children.
[Elderly Use]
No dose adjustment is required.
[Overdose]
High doses may cause arrhythmia, elevated transaminases, changes in renal function, and granulocytopenia.
[Pharmacology and Toxicology]
This drug specifically targets gastric mucosal parietal cells, reducing the activity of H+-K+-ATPase in these cells and thereby inhibiting gastric acid secretion. Compared with omeprazole, this drug has a weaker inhibitory effect on cytochrome P450 enzymes.
